Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF
|Numero di pagine||4|
|Rivista||American Journal of Hematology|
|Stato di pubblicazione||Published - 2009|
All Science Journal Classification (ASJC) codes
Siragusa, S., Tefferi, A., Cervantes, F., & Passamonti, F. (2009). Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients. American Journal of Hematology, 84, 140-143.